Home Wires

Our view on Resmed (RMD) is different to the other brokers

Michael Gable

Fairmont Equities

Our view on Resmed (RMD) is different to the other brokers. Of the 8 covering it, 7 rate it as a buy, with one neutral. When everyone is bullish, the contrarian trade normally wins out, doesn't it? You can read our views on RMD via the following link: (VIEW LINK) For a copy of the full report containing other trading and investment ideas, visit our website (VIEW LINK)

Michael Gable
Michael Gable
Managing Director
Fairmont Equities

Michael Gable is managing director of Fairmont Equities. We are a small boutique advisory that uniquely combines both fundamental and technical analysis. As a result, our analysis is featured regularly in the finance media such as the Australian...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment

most popular

Equities

Buy Hold Sell: 5 ASX disruptors taking on the giants

Livewire Markets

Equities

The critical mineral no one's watching (and our #1 ASX small cap pick)

Seneca Financial Solutions

Equities

Israel strikes Iran: Impacts on crude oil and the ASX 200

Livewire Markets

Education

Mark Mobius: Change is coming and most companies are not prepared

Livewire Markets

view all